Logo image of OCX

ONCOCYTE CORP (OCX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCX - US68235C2061 - Common Stock

3.2 USD
+0.47 (+17.22%)
Last: 6/17/2025, 8:05:27 PM
3.17 USD
-0.03 (-0.94%)
After Hours: 6/17/2025, 8:05:27 PM
Fundamental Rating

2

Overall OCX gets a fundamental rating of 2 out of 10. We evaluated OCX against 528 industry peers in the Biotechnology industry. OCX may be in some trouble as it scores bad on both profitability and health. OCX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OCX has reported negative net income.
  • OCX had a negative operating cash flow in the past year.
  • OCX had negative earnings in each of the past 5 years.
  • In the past 5 years OCX always reported negative operating cash flow.
OCX Yearly Net Income VS EBIT VS OCF VS FCFOCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • OCX has a worse Return On Assets (-96.52%) than 75.27% of its industry peers.
  • The Return On Equity of OCX (-570.19%) is worse than 79.57% of its industry peers.
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROIC N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCX Yearly ROA, ROE, ROICOCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 52.56%, OCX is in the better half of the industry, outperforming 77.24% of the companies in the same industry.
  • OCX's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for OCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
OCX Yearly Profit, Operating, Gross MarginsOCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

  • OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, OCX has more shares outstanding
  • The number of shares outstanding for OCX has been increased compared to 5 years ago.
  • OCX has a worse debt/assets ratio than last year.
OCX Yearly Shares OutstandingOCX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
OCX Yearly Total Debt VS Total AssetsOCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -7.51, we must say that OCX is in the distress zone and has some risk of bankruptcy.
  • OCX has a Altman-Z score of -7.51. This is in the lower half of the industry: OCX underperforms 69.00% of its industry peers.
  • OCX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • OCX's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. OCX is outperformed by 62.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -7.51
ROIC/WACCN/A
WACC8.92%
OCX Yearly LT Debt VS Equity VS FCFOCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • OCX has a Current Ratio of 3.75. This indicates that OCX is financially healthy and has no problem in meeting its short term obligations.
  • OCX's Current ratio of 3.75 is in line compared to the rest of the industry. OCX outperforms 43.01% of its industry peers.
  • A Quick Ratio of 3.70 indicates that OCX has no problem at all paying its short term obligations.
  • OCX has a Quick ratio (3.70) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.7
OCX Yearly Current Assets VS Current LiabilitesOCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

  • OCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.19%, which is quite impressive.
  • Looking at the last year, OCX shows a very strong growth in Revenue. The Revenue has grown by 178.48%.
  • The Revenue has been decreasing by -5.09% on average over the past years.
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%

3.2 Future

  • Based on estimates for the next years, OCX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.86% on average per year.
  • The Revenue is expected to grow by 197.76% on average over the next years. This is a very strong growth
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
OCX Yearly Revenue VS EstimatesOCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
OCX Yearly EPS VS EstimatesOCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • OCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCX Price Earnings VS Forward Price EarningsOCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCX Per share dataOCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • OCX's earnings are expected to grow with 21.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.55%
EPS Next 3Y21.86%

More info and screens

0

5. Dividend

5.1 Amount

  • OCX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOCYTE CORP

NASDAQ:OCX (6/17/2025, 8:05:27 PM)

After market: 3.17 -0.03 (-0.94%)

3.2

+0.47 (+17.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-06
Inst Owners56.3%
Inst Owner Change0%
Ins Owners0.97%
Ins Owner Change0%
Market Cap91.52M
Revenue(TTM)3.84M
Net Income(TTM)-58.26M
Analysts75
Price Target5.53 (72.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-178.01%
Min EPS beat(2)-347.17%
Max EPS beat(2)-8.85%
EPS beat(4)1
Avg EPS beat(4)-110.58%
Min EPS beat(4)-347.17%
Max EPS beat(4)36.24%
EPS beat(8)3
Avg EPS beat(8)-69.43%
EPS beat(12)6
Avg EPS beat(12)-56.88%
EPS beat(16)8
Avg EPS beat(16)-44.6%
Revenue beat(2)2
Avg Revenue beat(2)1470.69%
Min Revenue beat(2)1371.29%
Max Revenue beat(2)1570.08%
Revenue beat(4)2
Avg Revenue beat(4)707.66%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)1570.08%
Revenue beat(8)4
Avg Revenue beat(8)355.12%
Revenue beat(12)4
Avg Revenue beat(12)213.18%
Revenue beat(16)5
Avg Revenue beat(16)144.09%
PT rev (1m)20.37%
PT rev (3m)31.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.05%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)38.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)106.51%
Revenue NY rev (3m)195.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.81
P/FCF N/A
P/OCF N/A
P/B 8.96
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.13
BVpS0.36
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.56%
FCFM N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.45%
Cap/Sales 20.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.7
Altman-Z -7.51
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
EBIT growth 1Y55.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.32%
EBIT Next 3Y10.61%
EBIT Next 5YN/A
FCF growth 1Y47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.8%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOCYTE CORP / OCX FAQ

Can you provide the ChartMill fundamental rating for ONCOCYTE CORP?

ChartMill assigns a fundamental rating of 2 / 10 to OCX.


What is the valuation status for OCX stock?

ChartMill assigns a valuation rating of 1 / 10 to ONCOCYTE CORP (OCX). This can be considered as Overvalued.


Can you provide the profitability details for ONCOCYTE CORP?

ONCOCYTE CORP (OCX) has a profitability rating of 1 / 10.